These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 23461764)
1. Comparison of recombinant human erythropoietin and darbepoetin alpha in children. Can C; Emre S; Bilge I; Yilmaz A; Şirin A Pediatr Int; 2013 Jun; 55(3):296-9. PubMed ID: 23461764 [TBL] [Abstract][Full Text] [Related]
2. Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease. Chen HH; Tarng DC; Lee KF; Wu CY; Chen YC J Nephrol; 2008; 21(4):543-9. PubMed ID: 18651544 [TBL] [Abstract][Full Text] [Related]
3. Comparison of darbepoetin alpha and recombinant human erythropoietin for treatment of anemia in pediatric chronic kidney disease: a non-inferiority trial from India. Mazahir R; Anand K; Pruthi PK Eur J Pediatr; 2023 Jan; 182(1):101-109. PubMed ID: 36220980 [TBL] [Abstract][Full Text] [Related]
4. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR). Hertel J; Locay H; Scarlata D; Jackson L; Prathikanti R; Audhya P Am J Nephrol; 2006; 26(2):149-56. PubMed ID: 16636531 [TBL] [Abstract][Full Text] [Related]
5. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis]. Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875 [TBL] [Abstract][Full Text] [Related]
6. Oxidative stress, inflammation and nutritional status during darbepoetin alpha treatment in peritoneal dialysis patients. Malgorzewicz S; Lichodziejewska-Niemierko M; Lizakowski S; Liberek T; Lysiak-Szydlowska W; Rutkowski B Clin Nephrol; 2010 Mar; 73(3):210-5. PubMed ID: 20178720 [TBL] [Abstract][Full Text] [Related]
7. [Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa]. Molina M; García Hernández MA; Navarro MJ; Pérez Silva F; Cacho M; De Gracia MC Nefrologia; 2004; 24(1):54-9. PubMed ID: 15083958 [TBL] [Abstract][Full Text] [Related]
8. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Vanrenterghem Y; Bárány P; Mann JF; Kerr PG; Wilson J; Baker NF; Gray SJ; Kidney Int; 2002 Dec; 62(6):2167-75. PubMed ID: 12427142 [TBL] [Abstract][Full Text] [Related]
9. Randomized study of darbepoetin alfa and recombinant human erythropoietin for treatment of renal anemia in chronic renal failure patients receiving peritoneal dialysis. Li WY; Chu TS; Huang JW; Wu MS; Wu KD J Formos Med Assoc; 2008 Nov; 107(11):843-50. PubMed ID: 18971153 [TBL] [Abstract][Full Text] [Related]
10. A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritoneal dialysis patients. Mahajan S; Boulton H; Gokal R J Nephrol; 2004; 17(5):687-92. PubMed ID: 15593036 [TBL] [Abstract][Full Text] [Related]
11. Once-monthly darbepoetin alfa for maintaining hemoglobin levels in older patients with chronic kidney disease. Agarwal A; Silver MR; Walczyk M; Liu W; Audhya P J Am Med Dir Assoc; 2007 Feb; 8(2):83-90. PubMed ID: 17289537 [TBL] [Abstract][Full Text] [Related]
12. Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis. Wilhelm-Leen ER; Winkelmayer WC Am J Kidney Dis; 2015 Jul; 66(1):69-74. PubMed ID: 25636816 [TBL] [Abstract][Full Text] [Related]
13. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment. Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R; Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642 [TBL] [Abstract][Full Text] [Related]
14. Darbepoetin alfa for the treatment of anemia in pediatric patients with chronic kidney disease. Warady BA; Arar MY; Lerner G; Nakanishi AM; Stehman-Breen C Pediatr Nephrol; 2006 Aug; 21(8):1144-52. PubMed ID: 16724235 [TBL] [Abstract][Full Text] [Related]
15. Treatment of renal anaemia with erythropoiesis-stimulating agents in predialysis chronic kidney disease patients: Haemoglobin profile during the 6 months before initiation of dialysis. Kawahara K; Minakuchi J; Yokota N; Suekane H; Tsuchida K; Kawashima S Nephrology (Carlton); 2015 Dec; 20 Suppl 4():29-32. PubMed ID: 26456375 [TBL] [Abstract][Full Text] [Related]
16. Darbepoetin alfa (KRN321) administered intravenously once monthly maintains hemoglobin levels in peritoneal dialysis patients. Hiramatsu M; Kubota M; Iwasaki M; Akizawa T; Koshikawa S; Ther Apher Dial; 2008 Feb; 12(1):19-27. PubMed ID: 18257808 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of darbepoetin alfa for anemia in children with chronic kidney disease: a multicenter prospective study in Japan. Hattori M; Uemura O; Hataya H; Ito S; Hisano M; Ohta T; Fujinaga S; Kise T; Gotoh Y; Matsunaga A; Ito N; Akizawa T; Clin Exp Nephrol; 2014 Aug; 18(4):634-41. PubMed ID: 24013765 [TBL] [Abstract][Full Text] [Related]
18. Randomized equivalence study evaluating the possibility of switching hemodialysis patients receiving subcutaneous human erythropoietin directly to intravenous darbepoetin alfa. Chazot C; Terrat JC; Dumoulin A; Ang KS; Gassia JP; Chedid K; Maurice F; Canaud B; Ann Pharmacother; 2009 Feb; 43(2):228-34. PubMed ID: 19407262 [TBL] [Abstract][Full Text] [Related]
19. Darbepoetin alfa for the treatment of anemia in children undergoing peritoneal dialysis: a multicenter prospective study in Japan. Hattori M; Matsunaga A; Akioka Y; Fujinaga S; Nagai T; Uemura O; Nakakura H; Ashida A; Kamei K; Ito S; Yamada T; Goto Y; Ohta T; Hisano M; Komatsu Y; Itami N Clin Exp Nephrol; 2013 Aug; 17(4):582-8. PubMed ID: 23089940 [TBL] [Abstract][Full Text] [Related]